Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — H1 2023 Earnings Presentation
26 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, August 2023
Slide 1: 2023 Interim Presentation
2023 Interim Presentation August 2023 Strictly Private and Confidential
Slide 2: 1H 2023 achievements at a glance
1H 2023 achievements at a glance Commercial Bids Overseas Business SkyWalkerTM approved in US, Europe, Won 8 bids for Toumai® Brazil and Australia, with 5 units installed (3 new bids in 1H2023) in US, 1st unit installed in Europe; Highest among domestic players DFVision® obtained CE marking Revenue
Slide 3: Agenda
Agenda Business highlights Product pipeline update Financial review Appendix CONFIDENTIAL 2
Slide 4: Domestic Commercialization expansion - Successive orders from reputable hospitals
Domestic Commercialization expansion - Successive orders from reputable hospitals 4 products winning bids in 3 surgical specialties with more sales indications from other hospitals Achieved significant topline growth in 1H2023 winning bids with installed Toumai® 1st Chinese laparoscopic surgical rob
Slide 5: Footprint of global commercialization
Footprint of global commercialization 2 SkyWalkerTM to be installed in EU, first DFVision ® obtained CE operation in Sep mark in 1H23 Toumai® applied for CE mark EU United 5 SkyWalkerTM installed States China in US, with 30+ clinical operations performed Debut at Society of Robotic Surgery (SRS) Sky
Slide 6: Large scale clinical validation of Toumai
Large scale clinical validation of Toumai® LARGE VOLUME clinical validation operations 20+ 40+ Provinces Hospitals to ensure safety and reliability 1,200+ WIDE COVERAGE clinical procedures across developed completed up to date and lower tier cities Premium quality Safety and reliability confirmed
Slide 7: Large scale clinical validation of Toumai (cont'd)
Large scale clinical validation of Toumai® (cont’d) LEADING CAPABILITY HIGH FREQUENCY providing safer, easier and more intense validation with successive operations efficient solutions for difficult and complicated diseases The First Affiliated Hospital First of its kind completed with a Chinese- Zh
Slide 8: Large scale clinical validation of SkyWalker
Large scale clinical validation of SkyWalkerTM Wide coverage & Large volume 16 40+ Provinces Hospitals TKA for patient with 600+ TKA for patient with severe deformity post-severe-fracture internal fixation clinical procedures completed up to date Supporting multiple disciplines 1st 5G long range dom
Slide 9: Integration of 5G technology and surgical robot
Integration of 5G technology and surgical robot 1 2 1 2 2 1st 5,000 km 5G ultra-long- 1st 5G ultra-long-range robot- range robot-assisted assisted hysterectomy and 4 3 hepatectomy globally bilateral adnexectomy globally 4 3 4 1 3 1st 5G long range robot- 1st 5G long range robot-assisted Penetrated i
Slide 10: Leading domestic player to conduct large scale surgeon trainings
Leading domestic player to conduct large scale surgeon trainings Training center layout Active deployment of training centers in 1H2023 Training centers extensively established nationwide, covering most Chinese provinces and major cities, mainly through collaboration with reputable hospitals 35
Slide 11: Agenda
Agenda Business highlights Product pipeline update Financial review Appendix CONFIDENTIAL 10
Slide 12: Comprehensive product offering covering all major and fast-growing surgical specialties
Comprehensive product offering covering all 5 major and fast- growing surgical specialties 12 products covering 5 surgical specialties Development stage Medical Device Surgical Indicated Product Clinical Trial/ Specialty Product Application Classification Design Development Design Validation Clinica
Slide 13: Flagship product – Toumai Laparoscopic Surgical Robot
Flagship product – Toumai® Laparoscopic Surgical Robot 1st Domestic laparoscopic 1st Domestic laparoscopic surgical Surgical robots installed for surgical robot to realize robot received NMPA approval commercialization commercial installation Multiple generations of Toumai clinical progress Toumai®
Slide 14: Flagship product – SkyWalker Orthopedic Surgical Robot
Flagship product – SkyWalkerTM Orthopedic Surgical Robot The First and the only domestic orthopaedic surgical robot with NMPA, FDA,CE, ANVISA and TGA approvals The First domestic surgical robot to expand into global market Jun 2022 Dec 2022 Jul 2023 FDA Clearance Won First Bid TGA Approval Approved
Slide 15: Flagship product – DFVision 3D Electronic Laparoscope
Flagship product – DFVision® 3D Electronic Laparoscope Rapid commercialization – pioneer Upgraded system to further enrich the Decent sales in 1H23 among domestic brands product portfolio Stereo visualization The natural depth of field allows the surgeon to have intuitive observation High-definition
Slide 16: Natural Orifice Surgical Robot
Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Surgery application Product Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and control them for d
Slide 17: Panvascular and Percutaneous Surgical Robots
Panvascular and Percutaneous Surgical Robots R-ONE® Vascular Interventional Surgical Robot Mona Lisa Robotic Transperineal Prostate Biopsy System CE Marking CE Marking FDA approval Real-time 2D ultrasound images Designed to operate with precision displayed on the monitor during the and perform s
Slide 18: Strong industrial operation capabilities for surgical robots
Strong industrial operation capabilities for surgical robots 1,152 Multilayered supply chain system applications In-house designed components (1029 invention patents) 351 Scalable production of Toumai®, overseas applications SkyWalkerTM and consumables (94 granted) Annual capacity over 100 units of
Slide 19: Agenda
Agenda Business highlights Product pipeline update Financial review Appendix CONFIDENTIAL 18
Slide 20: Consolidated Financial Performance
Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH-FLOW (RMB (RMB (RMB million) million) million) SBP +18% +13% 682.8 741.6 47.6 74.1 544.7 -36% 132% 463.5 -20% 71.2 62.8 471.2 416.6 20.6 608.7 473.6 400.7 1.0 22A 1H 22A 2H 23A 1H 22A 1H 22A 2H 23A 1H 22A 1H 22A 2H 23A 1H New produc
Slide 21: Operating Expenses
Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) SBP (RMB million) SBP (RMB million) SBP -7% 419.4 +98% +19% -26% 336.4 48.8 311.7 41.1 43.5 119.9 +6% 126.9 105.3 9.7 12.2 -26% 370.6 77.6 295.3 64.2 65.1 15.7 268.2 8.4 15.5 110.2 114.7 13.2 89.6 55.7 51.9 62.1 22A 1H 22
Slide 22: Agenda
Agenda Business highlights Commercialization Product pipeline update Financial review Appendix CONFIDENTIAL 21
Slide 23: Financial Statement – Balance Sheet
Financial Statement – Balance Sheet Unit: RMB'000 30 June 2023 31 Dec 2022 Var. Unit: RMB'000 30 June 2023 31 Dec 2022 Var. Non-current assets CAPITAL AND RESERVES Property, plant and equipment 409,004 491,576 -17% Share capital 958,594 958,594 0% Intangible assets 5,832 7,053 -17% Reserves (5,502)
Slide 24: Financial Statement – P&L
Financial Statement – P&L Unit: RMB'000 23A 1H 22A 1H Var. Revenue 47,603 1,048 4442% Cost of sales (25,535) (357) 7053% Gross profit 22,068 691 3094% Other net income (23,214) 16,290 -243% Selling and marketing expenses (126,907) (64,160) 98% Administrative expenses (77,597) (65,139) 19% Research a
Slide 25: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd. (上海微创医疗机器人（集团） 股份有限公司) , and no p
Slide 26: Strictly Private and Confidential
Strictly Private and Confidential 25 CONFIDENTIAL
Shanghai MicroPort MedBot (Group) — H1 2023 Earnings Presentation on 6ix